We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




CT Attenuation Measurements Can Differentiate Bone Tumors

By MedImaging International staff writers
Posted on 31 Aug 2016
Image: A calcaneous bone with a benign enostosis (Photo courtesy of James Wittig).
Image: A calcaneous bone with a benign enostosis (Photo courtesy of James Wittig).
A new study suggests that computerized tomography (CT) attenuation measurements can be used to distinguish untreated osteoblastic metastases from benign bone lesions.

Researchers at Massachusetts General Hospital (MGH; Boston, USA) conducted a study in 62 patients with 279 sclerotic bone lesions found at CT. The cause of the sclerotic lesions was then assessed histologically, determining there were 126 benign enostoses (bone islands) in 37 patients, and 153 osteoblastic metastases in 25 patients. The researchers then performed an analysis of the CT images to determine sensitivity, specificity, AUC, 95% confidence intervals, and cutoff values of CT attenuation to help differentiate metastases from enostoses.

The researchers concluded that CT attenuation measurements can be used to distinguish untreated osteoblastic metastases from enostoses, and that a mean attenuation of 885 Hounsfield units (HU) and a maximum attenuation of 1,060 HU provide reliable thresholds below which a metastatic lesion is the favored diagnosis. According to the researchers, the detection of metastatic disease is crucial because it allows accurate diagnosing and determination of prognosis and can drastically change treatment. The study was published in the August 2016 issue of the American Journal of Roentgenology.

“While imaging has become an integral part of diagnosing patients presenting with malignancy, it can be confusing when an osteoblastic lesion is identified in the presence and absence of a primary malignancy,” concluded lead author Connie Chang, MD, of the MGH department of radiology, and colleagues. “As CT use has increased, the frequency of incidentally detected lesions has also increased.”

The Hounsfield scale is a quantitative scale for describing radiodensity, in which distilled water at standard pressure and temperature is defined as zero HU, while the radiodensity of air under the same conditions is defined as -1000 HU; one HU represents a change of 0.1% of the attenuation coefficient of water. A practical application of this is in evaluation of tumors, wherein an adrenal tumor with a radiodensity of less than 10 HU is rather fatty in composition and almost certainly benign.

Related Links:
Massachusetts General Hospital

Breast Localization System
MAMMOREP LOOP
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Portable X-ray Unit
AJEX140H
Adjustable Mobile Barrier
M-458

Channels

Nuclear Medicine

view channel
Image: LHSCRI scientist Dr. Glenn Bauman stands in front of the PET scanner (Photo courtesy of LHSCRI)

New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer

Detecting recurrent prostate cancer remains one of the most difficult challenges in oncology, as standard imaging methods such as bone scans and CT scans often fail to accurately locate small or early-stage tumors.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.